Tofacitinib as a Pragmatic Treatment Choice for Alopecia Areata: A Retrospective Review

    January 2022 in “ Dermatologic Therapy
    Sarah Benton, Ronda S. Farah, Rebecca Freese, Maria Hordinsky
    Image of study
    TLDR Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
    The study titled "Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review" conducted a retrospective analysis of 35 alopecia areata (AA) patients treated with tofacitinib, a Janus kinase (JAK) inhibitor, between January 2013 and July 2019. The study aimed to measure the safety, efficacy, and practicality of off-label use of tofacitinib in AA. The results showed no serious adverse events. Clinically significant scalp regrowth was observed in 83.9% of patients, and near total/total regrowth was experienced by 32.3% of patients. The study concluded that tofacitinib was safe, effective, and practical for this cohort of 35 AA patients.
    Discuss this study in the Community →

    Cited in this study

    18 / 18 results

    Related

    1 / 1 results